Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 10/20 | 0.63 |
| ▸ | GAB1 | Q13480 | 4/20 | 0.63 |
| ▸ | IRS1 | P35568 | 3/20 | 0.63 |
| ▸ | PKM | P14618 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5831475 | 0.90 | AKT1 (0.67) | AKT1GAB1IRS1PKMALDH1A1 | |
| SCHEMBL5831043 | 0.87 | AKT1 (0.63) | AKT1GAB1IRS1PKMALDH1A1 | |
| SCHEMBL5830940 | 0.85 | ATM (0.57) | AKT1GAB1IRS1PKMALDH1A1 | |
| SCHEMBL3251447 | 0.82 | AKT1 (0.45) | AKT1GAB1IRS1 | |
| SCHEMBL5831266 | 0.82 | AKT1 (0.44) | AKT1GAB1IRS1ALDH1A1MEN1 | |
| SCHEMBL3611585 | 0.80 | KMT2A (0.55) | AKT1GAB1IRS1PKMALDH1A1 | |
| SCHEMBL5831319 | 0.78 | AKT1 (0.60) | AKT1GAB1IRS1PKMALDH1A1 | |
| SCHEMBL5831265 | 0.78 | AKT1 (0.59) | AKT1GAB1IRS1PKMALDH1A1 | |
| SCHEMBL6614287 | 0.77 | FFAR4 (0.44) | AKT1GAB1IRS1ALDH1A1ATM | |
| SCHEMBL283045 | 0.77 | AKT1 (1.00) | AKT1GAB1IRS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030130258-A1 | Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics | BIOVITRUM AB (SE) | 2003-07-10 | — | — | US | claimed |
| US-7074788-B2 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2006-07-11 | — | — | US | disclosed |
| WO-2004113310-A1 | USE OF AN INHIBITOR OF 11-B-HYDROXYSTEROID DEHYDROGENASE TYPE 1 COMPOUNDS FOR PROMOTING WOUND HEALING | BIOVITRUM AB (SE) | 2004-12-29 | — | — | WO | disclosed |
| US-20030130258-A1 | Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics | BIOVITRUM AB (SE) | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130258-A1 | Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics | CPT1A, HSD11B1, CES1 | AKT1 2974/4885GAB1 2088/4885IRS1 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.